JP5830096B2 - 血漿由来インターα阻害タンパク質（ＩａＩｐ）の製造方法 - Google Patents

血漿由来インターα阻害タンパク質（ＩａＩｐ）の製造方法 Download PDF

Info

Publication number
JP5830096B2
JP5830096B2 JP2013521858A JP2013521858A JP5830096B2 JP 5830096 B2 JP5830096 B2 JP 5830096B2 JP 2013521858 A JP2013521858 A JP 2013521858A JP 2013521858 A JP2013521858 A JP 2013521858A JP 5830096 B2 JP5830096 B2 JP 5830096B2
Authority
JP
Japan
Prior art keywords
iaip
precipitate
fraction
composition
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013521858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013535468A5 (enExample
JP2013535468A (ja
Inventor
ショーン エフ． ベアーストウ
ショーン エフ． ベアーストウ
ジェニファー ハットセル
ジェニファー ハットセル
シンデュ ラマチャンドラン
シンデュ ラマチャンドラン
Original Assignee
バクスター、インターナショナル、インコーポレイテッド
バクスター ヘルスケア エス．エー．
バクスター ヘルスケア エス．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バクスター、インターナショナル、インコーポレイテッド, バクスター ヘルスケア エス．エー．, バクスター ヘルスケア エス．エー． filed Critical バクスター、インターナショナル、インコーポレイテッド
Publication of JP2013535468A publication Critical patent/JP2013535468A/ja
Publication of JP2013535468A5 publication Critical patent/JP2013535468A5/ja
Application granted granted Critical
Publication of JP5830096B2 publication Critical patent/JP5830096B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2013521858A 2010-07-23 2011-07-22 血漿由来インターα阻害タンパク質（ＩａＩｐ）の製造方法 Expired - Fee Related JP5830096B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36733110P 2010-07-23 2010-07-23
US61/367,331 2010-07-23
PCT/US2011/045099 WO2012012773A1 (en) 2010-07-23 2011-07-22 Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma

Publications (3)

Publication Number Publication Date
JP2013535468A JP2013535468A (ja) 2013-09-12
JP2013535468A5 JP2013535468A5 (enExample) 2014-09-11
JP5830096B2 true JP5830096B2 (ja) 2015-12-09

Family

ID=44534634

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013521858A Expired - Fee Related JP5830096B2 (ja) 2010-07-23 2011-07-22 血漿由来インターα阻害タンパク質（ＩａＩｐ）の製造方法

Country Status (14)

Country Link
US (2) US8841248B2 (enExample)
EP (1) EP2596014B1 (enExample)
JP (1) JP5830096B2 (enExample)
KR (1) KR20130093607A (enExample)
CN (1) CN103119058A (enExample)
AU (1) AU2011280907B2 (enExample)
BR (1) BR112013001753A2 (enExample)
CA (1) CA2806645A1 (enExample)
CO (1) CO6680653A2 (enExample)
EA (1) EA201390156A1 (enExample)
ES (1) ES2717177T3 (enExample)
MX (1) MX2013000958A (enExample)
SG (1) SG187599A1 (enExample)
WO (1) WO2012012773A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932365B2 (en) 2003-11-08 2011-04-26 Pro Thera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
JP5793076B2 (ja) 2008-05-28 2015-10-14 プロセラ バイオロジクス， インコーポレイテッド 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。
US8546548B2 (en) 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
EP2596014B1 (en) 2010-07-23 2018-11-28 Baxalta GmbH Manufacture of inter-alpha-inhibitor proteins (iaip) from plasma
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
US9572872B2 (en) 2012-09-09 2017-02-21 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) * 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
WO2017062536A2 (en) * 2015-10-06 2017-04-13 Kieu Hoang A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
CA3036553A1 (en) 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
KR102587810B1 (ko) 2017-04-25 2023-10-11 프로테라 바이오로직스, 인크. 인터-알파 억제제 단백질을 정량화하는 방법
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
WO2020086879A1 (en) * 2018-10-24 2020-04-30 Prothera Biologics, Inc. Inter-alpha inhibitor proteins and methods of use thereof
CN109867717A (zh) * 2019-04-01 2019-06-11 山西瑞亚力生物技术有限公司 一种血浆中α1微球蛋白的提取方法
CN114096558B (zh) * 2019-07-04 2024-10-01 德国杰特贝林生物制品有限公司 纯化c1-inh的方法
MX2022011950A (es) * 2020-03-31 2022-10-21 Takeda Pharmaceuticals Co Metodo para producir una preparacion de inmunoglobulina a partir de plasma con reduccion del inhibidor de c-1.
EP4240757A2 (en) * 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
AU2021377336A1 (en) 2020-11-16 2023-07-06 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins
CN119300842A (zh) * 2022-05-02 2025-01-10 武田药品工业株式会社 通过超滤从血浆制备科恩池浓缩物的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2711371B1 (fr) 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
DE59509979D1 (de) * 1995-09-22 2002-02-07 Zlb Bioplasma Ag Bern Verfahren zur Gewinnung von Immunglobulinen aus Fraktionen, die bei der Fraktionierung von menschlichem Blutplasma entstehen
AU2002216968A1 (en) 2000-10-13 2002-04-22 Octapharma Ag Plasma fraction containing bikunin, method for the production thereof and use of the same
US7932365B2 (en) 2003-11-08 2011-04-26 Pro Thera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
CN101160133B (zh) * 2004-11-05 2013-01-09 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
ES2595059T3 (es) * 2007-03-20 2016-12-27 Csl Behring Gmbh Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano
JP5793076B2 (ja) * 2008-05-28 2015-10-14 プロセラ バイオロジクス， インコーポレイテッド 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。
WO2011011753A1 (en) 2009-07-23 2011-01-27 Baxter International Inc. Manufacture of factor h (fh) and fh-derivatives from plasma
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
EP2596014B1 (en) 2010-07-23 2018-11-28 Baxalta GmbH Manufacture of inter-alpha-inhibitor proteins (iaip) from plasma

Also Published As

Publication number Publication date
US20120053113A1 (en) 2012-03-01
KR20130093607A (ko) 2013-08-22
BR112013001753A2 (pt) 2016-05-31
EP2596014B1 (en) 2018-11-28
ES2717177T3 (es) 2019-06-19
AU2011280907B2 (en) 2016-02-04
WO2012012773A1 (en) 2012-01-26
SG187599A1 (en) 2013-03-28
US9505814B2 (en) 2016-11-29
MX2013000958A (es) 2013-11-20
EA201390156A1 (ru) 2014-01-30
US8841248B2 (en) 2014-09-23
EP2596014A1 (en) 2013-05-29
US20150045538A1 (en) 2015-02-12
CA2806645A1 (en) 2012-01-26
CO6680653A2 (es) 2013-05-31
AU2011280907A1 (en) 2013-02-07
CN103119058A (zh) 2013-05-22
JP2013535468A (ja) 2013-09-12

Similar Documents

Publication Publication Date Title
JP2013535468A (ja) 血漿由来インターα阻害タンパク質（ＩａＩｐ）の製造方法
JP6592120B2 (ja) 微細二酸化シリコンを用いた処理によるセリンプロテアーゼ除去法
US9109044B2 (en) Manufacture of factor H (FH) and FH-derivatives from plasma
US20130195897A1 (en) Removal of serine proteases by treatment with finely divided silicon dioxide
BR112014020602B1 (pt) Método para a fabricação de uma composição de imunoglobulina igg enriquecida
US20140275496A1 (en) Isolation of factor h from fraction i paste
HK40079365A (en) Removal of serine proteases by treatment with finely divided silicon dioxide
HK1183449B (en) Removal of serine proteases by treatment with finely divided silicon dioxide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140722

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20140722

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20140813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141118

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150219

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150918

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151023

R150 Certificate of patent or registration of utility model

Ref document number: 5830096

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees